期刊文献+

蒽环类药物普通制剂及脂质体制剂的心脏毒性研究进展 被引量:4

Research progress of cardiotoxicity of conventional and liposomal anthracyclines
下载PDF
导出
摘要 蒽环类药物属于抗肿瘤抗生素,为细胞周期靶向非特异性药物,具有广谱、强效的特点,临床上广泛用于实体肿瘤和恶性血液系统肿瘤的治疗。但是,因为容易引起心脏毒性事件而使其临床应用受到了一定程度的限制。经多年研究表明,与蒽环类药物普通制剂相比,脂质体制剂不但疗效相当,而且能减轻心脏毒性。本文就蒽环类药物普通制剂和脂质体制剂心脏毒性的流行病学、发生机制和防治措施作一综述,以期为其临床应用提供指导。 Anthracyclines,antitumor antibiotics,and cell cycle targeted nonspecific drugs with broad-spectrum and high anti-tumor activity,have been widely used in solid tumors and hematologic malignancies.Their clinical use,however,is sometimes limited by the development of cardiotoxicity.Liposomal anthracyclines can decrease cardiotoxicity without decreasing the efficacy.This paper overviews the epidemiology,mechanism,prevention and treatment of cardiotoxicity of anthracycline common preparations and liposomes,in order to provide guidance for their clinical application.
作者 高翠霞 王蕾 白彬 李晓晶 彭悦颖 张聪聪 胡子鉴 吕承 李海燕 GAO Cuixia;WANG Lei;BAI Bin;LI Xiaojing;PENG Yueying;ZHANG Congcong;HU Zijian;LV Cheng;LI Haiyan(Department of Medicine, CSPC ZhongQi Pharmaceutical Technology (Shijiazhuang);Co., Ltd., Shanghai 200040, China)
出处 《临床肿瘤学杂志》 CAS 2022年第1期88-93,共6页 Chinese Clinical Oncology
关键词 蒽环类药物 脂质体蒽环类药物 心脏毒性 Anthracyclines Liposomal anthracyclines Cardiotoxicity
  • 相关文献

参考文献2

二级参考文献37

  • 1Cvetkovi'c RS,Scott LJ.Dexrazoxane:a review of its use for cardioprotection during anthracycline chemotherapy[J].Drugs,2005,65(7):1005-1024.
  • 2Barry E,Alvarez JA,Scully RE,et al.Anthracycline-induced cardiotoxicity:course,pathophysiology,prevention and management[J].Expert Opin Pharmacother,2007,8 (8):1039-1058.
  • 3Lipshultz SE,Lipsitz SR,Sallan SE,et al.Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia[J].J Clin Oncol,2005,23(12):2629-2636.
  • 4Lipshultz SE,Colan SD,Gelber RD,et al.Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood[J].N EnglJ Med,1991,324(12):808-815.
  • 5Von Hoff DD,Layard MW,Basa P,et al.Risk factors for doxorubicin-induced congestive heart failure[J].Ann Intern Med,1979,91(5):710-717.
  • 6Swain SM,Whaley FS,Ewer MS,et al.Congestive heart failure in patients treated with doxorubicin:a retrospective analysis of three trials[J].Cancer,2003,97 (11):2869-2879.
  • 7Keefe DL.Anthracycline-induced cardiomyopathy[J].Semin Oncol,2001,28(4 Suppl 12):2-7.
  • 8Ganame J,Claus P,Uyttebroeck A,et al.Myocardial dysfunction late after low-dose anthracycline treatment in asymptomatic pediatric patients[J].J Am Soc Echocardiogr,2007,20 (12):1351-1358.
  • 9Robert J,Morvan VL,Smith D,et al.Predicting drug response and toxicity based on gene polymorphisms[J].Crit Rev Oncol Hematol,2005,54(3):171-196.
  • 10Lipshultz SE,Rifai N,Sallan SE,et al.Predictive value of cardiac troponin T in pediatric patients at risk for myocardial injury[J].Circulation,1997,96 (8):2641-2648.

共引文献263

同被引文献64

引证文献4

二级引证文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部